Skip to Content

Fycompa (perampanel) Disease Interactions

There are 5 disease interactions with Fycompa (perampanel):

Major

Perampanel (applies to Fycompa) renal impairment

Major Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction

Perampanel should be used with caution in patients with moderate renal impairment, and slower titration may be considered. No dose adjustment is required in patients with mild renal impairment. Care should be taken when prescribing this agent in patients with renal impairment, and close monitoring of renal function is recommended. The use of perampanel in patients with severe renal impairment or patients undergoing hemodialysis is not recommended.

Moderate

Antiepileptics (applies to Fycompa) suicidal tendency

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Depression, Psychosis

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs across multiple indications in either monotherapy or adjunctive therapy for a median treatment duration of 12 weeks (up to a maximum of 24 weeks) showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. The estimated rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% for 16,029 placebo-treated patients, representing an increase of approximately one case for every 530 patients treated. There were four suicides in AED-treated patients and none in placebo-treated patients, although the number is too small to establish any causal relationship. The increased risk of suicidal thoughts or behavior was observed as early as one week after starting AEDs and persisted for the duration of treatment assessed. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Therapy with AEDs should be administered cautiously in patients with depression or other psychiatric disorders. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. For clinically significant or persistent symptoms, a dosage reduction or treatment withdrawal should be considered. If patients have symptoms of suicidal ideation or behavior, treatment should be discontinued.

Moderate

Perampanel (applies to Fycompa) elevated triglycerides

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Hyperlipidemia

Increased levels of triglycerides have occurred in patients using perampanel. Care should be taken when prescribing this agent to patients with high triglycerides levels, and close monitoring of lipid profile is recommended during therapy.

Moderate

Perampanel (applies to Fycompa) weight gain

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Obesity

Weight gain has occurred with the use of perampanel. Care should be taken when prescribing this agent to patients predisposed to weight gain, and regular monitoring of weight is recommended.

Moderate

Perampanel – hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of perampanel in patients with severe hepatic impairment is not recommended. Dosage adjustments are recommended in patients with mild or moderate hepatic impairment as the half-life of perampanel may increase in these patients. Care should be exercised when prescribing this agent to patients with hepatic impairment, and close monitoring of liver function is recommended.

Fycompa (perampanel) drug interactions

There are 274 drug interactions with Fycompa (perampanel)

Fycompa (perampanel) alcohol/food interactions

There are 3 alcohol/food interactions with Fycompa (perampanel)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.